UnipharDUB:UPR +0.66%82 PB Ratio is 2.95 as of Jun. 26, 2026, which is 8% above its 10-year median of 2.72. GuruFocus rates DUB:UPR with a GF Score™ of 82/100 and a GF Value™ of €3.64 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 112 Medical Distribution companies, Uniphar ranks worse than 79.46% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Uniphar's share price is €4.60. Uniphar's Book Value per Share for the quarter that ended in Dec. 2025 was €1.56. Hence, Uniphar's PB Ratio of today is 2.95.
Warning Sign:
Uniphar PLC stock PB Ratio (=2.98) is close to 3-year high of 3.15.
The historical rank and industry rank for Uniphar's PB Ratio or its related term are showing as below:
DUB:UPR'
s PB Ratio Range Over the Past 10 Years
Min: 1.31 Med: 2.72 Max: 6.5
Current: 2.95
During the past 10 years, Uniphar's highest PB Ratio was 6.50. The lowest was 1.31. And the median was 2.72.
DUB:UPR's PB Ratio is ranked worse than 79.46% of 112
companies
in the Medical Distribution industry
Industry Median: 1.03
vs DUB:UPR: 2.95
During the past 12 months, Uniphar's average Book Value Per Share Growth Rate was 6.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 13.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 16.20% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Uniphar was 18.00% per year. The lowest was 13.70% per year. And the median was 16.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Uniphar PB Ratio Related Terms
Uniphar PB Ratio Historical Data
* Premium members only.
The historical data trend for Uniphar's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Uniphar's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Uniphar PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Uniphar's PB Ratio distribution charts can be found below:
* The bar in red indicates where Uniphar's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Uniphar's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Uniphar (DUB:UPR) has a PB Ratio of 2.95 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Uniphar and its competitors. This is near median its historical median of 2.72. Over the past decade, Uniphar's PB Ratio has ranged from 1.31 to 6.50. According to the industry distribution chart, Uniphar ranks #89 out of 112 companies in the Medical Distribution industry, placing it in the top 79.5%.
Is Uniphar's PB Ratio too high?
Uniphar's current PB Ratio of 2.95 is near median its 10-year median of 2.72. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 6.50. The Medical Distribution industry median PB Ratio is 1.03. Uniphar's value of 2.95 is 186.4% above this industry median. Based on the distribution chart, Uniphar ranks #89 out of 112 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Uniphar has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Uniphar ranks #89 out of 112 companies for PB Ratio. This places Uniphar in the lower half of its industry. The industry median PB Ratio is 1.03. Uniphar's value of 2.95 is 186.4% above this benchmark. Historically, Uniphar's own PB Ratio has ranged from 1.31 to 6.50 over the past decade. While the company's 10-year median is 2.72 vs. the industry median of 1.03, Uniphar has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.03, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Uniphar's current PB Ratio of 2.95 is 186.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Uniphar and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Uniphar's current PB Ratio is 2.95, which is near median its own 10-year median of 2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.64, compared to a current price of €4.60 — trading 26.4% above its estimated fair value. The current PB Ratio is 2.95, which is near median its 10-year median of 2.72 and 186.4% above the Medical Distribution industry median of 1.03. Uniphar's overall GF Score™ is 82/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current PB Ratio is 2.95 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Uniphar (DUB:UPR) Overvalued in 2026?
Based on GuruFocus' analysis, Uniphar stock appears to be overvalued.
The current stock price of €4.60 is trading 26.4% above its estimated GF Value™ of €3.64.
GuruFocus considers Uniphar to be Modestly Overvalued.
Key valuation signals for DUB:UPR:
PB Ratio: 2.95 (near median its 10-year median of 2.72)
GF Value™: €3.64 vs. price of €4.60 (26.4% above fair value)
Industry Position: 186.4% above the Medical Distribution median (#89 of 112)
No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
82GF Score
Get the complete analysis for DUB:UPR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DUB:UPR has been successfully added to your 
